Editorial
Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma Masahiro Nozawa, Hirotsugu Uemura Department of Urology, Kinki University Faculty of Medicine, Japan Correspondence to: Masahiro Nozawa, MD, PhD. 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511, Japan. Email:
[email protected]. Submitted Apr 15, 2012. Accepted for publication May 03, 2012. doi: 10.3978/j.issn.2223-4683.2012.05.02 Scan to your mobile device or view this article at: http://www.amepc.org/tau/article/view/636/682
Sunitinib is globally approved for treatment of advanced renal cell carcinoma (RCC) at a dosage of 50 mg/day with four weeks on treatment and two weeks off, based on a randomized phase III trial in which its superiority over interferon alpha was established as first-line therapy for patients with metastatic RCC (1). On the other hand, continuous daily dosing of sunitinib at a dosage of 37.5 mg/day may be expected to provide consistent antitumor activity with a better safety profile compared with the 50 mg/day intermittent schedule according to two phase II trials (2,3). The recently published paper reported the result of a very interesting randomized phase II study called “Renal EFFECT Trial”, in which the efficacy and safety of sunitinib was directly compared between the 50 mg/day intermittent schedule and the continuous 37.5 mg/day as first-line therapy for patients with advanced RCC (4). In this study, patients with treatment-naïve, clear cell advanced RCC were randomly assigned in a 1:1 ratio to receive sunitinib 50 mg/day with four weeks on treatment and two weeks off (schedule 4/2) or 37.5 mg/day on a continuous daily dosing schedule (CDD), with 146 patients in each arm. The primary end point was time to tumor progression (TTP). As a result, although statistically not significant, a longer TTP and progression-free survival (PFS) was observed with the 4/2 schedule. Median TTP in the 4/2 schedule and CDD arms was 9.9 months (95% CI, 7.0 to 13.4 months) and 7.1 months (95% CI, 6.8 to 9.7 months), respectively (hazard ratio [HR], 0.77; 95% CI, 0.57 to 1.04; P=0.090). Median PFS was 8.5 months (95% CI, 6.9 to 11.1 months) and 7.0 months (95% CI, 6.0 to 8.7 months) in the schedule 4/2 and CDD arms, respectively (HR, 0.77; 95% CI, 0.58 to 1.02; P=0.070). No significant difference between the schedule 4/2 and CDD © Translational Andrology and Urology. All rights reserved.
arms was observed in objective response rate (32% and 28%, respectively), stable disease rate (43% and 49%, respectively), or overall survival (median, 23.1 and 23.5 months, respectively). Patient baseline characteristics were similar between both arms, although a slightly higher number of patients had a lower Karnofsky performance status, MSKCC poor risk disease, and liver metastases in the CDD arm compared with the schedule 4/2 arm. When analyzed by the MSKCC risk criteria, however, the relative increase in TTP with the 4/2 schedule was most pronouncedly shown in the favorable-risk (HR, 0.56; 95% CI, 0.29 to 1.07; P=0.075) rather than in the intermediate or poorrisk group. Moreover, in the multivariable analysis which assessed an independent relationship for each variable studied among a range of pretreatment clinical features, the trend for longer TTP (HR, 0.74; 95% CI, 0.53 to 1.01; P=0.061) and PFS (HR, 0.75; 95% CI, 0.55 to 1.02; P=0.071) with schedule 4/2 was observed. Predictors for TTP were baseline lung or bone metastases within the multivariable analysis. What about safety and tolerability? Median treatment duration was five months (range,